Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients

World Journal of Gastroenterology

Volumn 20, Issue 16, 2014, Pages 4702-4711

  Shen, Feng ^a   Zheng, Rui Dan ^b   Mi, Yu Qiang ^c   Wang, Xiao Ying ^a   Pan, Qin ^a   Chen, Guang Yu ^a   Cao, Hai Xia ^a   Chen, Ming Li ^a   Xu, Liang ^c   Chen, Jian Neng ^b   Cao, Yi ^a   Zhang, Rui Nan ^a   Xu, Lei Ming ^a   Fan, Jian Gao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b 909th Hospital of Joint Logistics Support Force   (China)

^c Tianjin Hospital of Infectious Diseases   (China)

Author keywords

Chronic hepatitis b; Controlled attenuation parameter; Fatty liver; Nonalcoholic; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED ATTENUATION PARAMETER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; ELASTOGRAPHY; FATTY LIVER; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MIDDLE AGED; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PROSPECTIVE STUDY; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; AREA UNDER THE CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CHI SQUARE DISTRIBUTION; CHINA; CLINICAL TRIAL; ETHNOLOGY; EVALUATION STUDY; LIVER; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; PATHOLOGY; PREDICTIVE VALUE; RISK; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; CHINA; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; LINEAR MODELS; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84899653695     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i16.4702     Document Type: Article

References (34)

1. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36: 13-20 [PMID: 21920839 DOI: 10.1016/j.clinre.2011.08.001]
2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]
3. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642 [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014]
4. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117 [PMID: 10644271 DOI: 10.7326/0003-4819- 132-2-200001180-00004]
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112 [PMID: 16447287]
6. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42: 5-13 [PMID: 15962320 DOI: 10.1002/hep.20750]
7. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 Suppl 4: 6-8 [PMID: 10485854 DOI: 10.1136/gut.45.2008.iv1]
8. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, Poupon R, Cardoso AC, Marcellin P, Douvin C, de Ledinghen V, Trinchet JC, Beaugrand M. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244-253 [PMID: 22404722 DOI: 10.1111/j.1365-2893.2011.01534.x]
9. Kumar M, Rastogi A, Singh T, Behari C, Gupta E, Garg H, Kumar R, Bhatia V, Sarin SK. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol 2013; 28: 1194-1201 [PMID: 23425053 DOI: 10.1111/jgh.12134]
10. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, Sandrin L, Miette V. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-1835 [PMID: 20870345 DOI: 10.1016/j.ultr asmedbio.2010.07.005]
11. de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911-918 [PMID: 22672642 DOI: 10.1111/j.1478-3231.2012.02820.x]
12. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, Duarte-Rojo A, Wong D, Crotty P, Elkashab M. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32: 902-910 [PMID: 22435761 DOI: 10.1111/j.1478-3231.2012.02781.x]
13. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-210 [PMID: 19014878 DOI: 10.1016/j.jhep.2008.10.010]
14. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18: 163-166). J Dig Dis 2011; 12: 38-44 [PMID: 21276207 DOI: 10.1111/j.1751-2980.2010.00476.x]
15. Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010; 4: 386-395 [PMID: 20305758 DOI: 10.1007/s12072-010-9163-9]
16. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]
17. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-353 [PMID: 21520200 DOI: 10.1002/hep.24376]
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293 [PMID: 8690394 DOI: 10.1002/hep.510240201]
19. Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, Marzano A, Rizzetto M. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54: 64-71 [PMID: 20932598 DOI: 10.1016/j.jhep.2010.06.022]
20. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-526 [PMID: 16941687 DOI: 10.1002/hep.21347]
21. Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Chan HY, Woo J, Chan FK, Chan HL. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012; 56: 533-540 [PMID: 22027575 DOI: 10.1016/j.jhep.2011.09.013]
22. Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One 2012; 7: e34198 [PMID: 22479562 DOI: 10.1371/journal. pone.0034198]
23. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10 [PMID: 16375767 DOI: 10.1186/1476-5926-4-10]
24. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33 [PMID: 17081293 DOI: 10.1186/1471-230X-6-33]
25. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42: 503-508 [PMID: 19766548 DOI: 10.1016/j.dld.2009.08.002]
26. Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, Manns MP, Schulze-Osthoff K, Bantel H. Prospective biopsycontrolled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012; 55: 455-464 [PMID: 21993925 DOI: 10.1002/hep.24734]
27. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-445 [PMID: 19604596 DOI: 10.1016/j.jhep.2009.05.023]
28. Corradini E, Pietrangelo A. Iron and steatohepatitis. J Gastroenterol Hepatol 2012; 27 Suppl 2: 42-46 [PMID: 22320915 DOI: 10.1111/j.1440-1746.2011.07014.x]
29. Hatta T, Fujinaga Y, Kadoya M, Ueda H, Murayama H, Kurozumi M, Ueda K, Komatsu M, Nagaya T, Joshita S, Kodama R, Tanaka E, Uehara T, Sano K, Tanaka N. Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging: a prospective study in biopsy-proven nonalcoholic fatty liver disease. J Gastroenterol 2010; 45: 1263-1271 [PMID: 20625773 DOI: 10.1007/s00535-010-0277-6]
30. Kim BK, Fung J, Yuen MF, Kim SU. Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol 2013; 19: 1890-1900 [PMID: 23569334 DOI: 10.3748/wjg.v19.i12.1890]
31. Recio E, Cifuentes C, Macías J, Mira JA, Parra-Sánchez M, Rivero-Juárez A, Almeida C, Pineda JA, Neukam K. Interob- server concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol 2013; 25: 905-911 [PMID: 23459105 DOI: 10.1097/MEG.0b013e32835f4c3d]
32. Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Takahashi S, Arihiro K, Chayama K. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res 2013; 43: 1182-1189 [PMID: 23551911 DOI: 10.1111/hepr.12094]
33. Audière S, Charbit M, Angelini ED, Oudry J, Sandrin L. Measurement of the skin-liver capsule distance on ultrasound RF data for 1D transient elastography. Med Image Comput Comput Assist Interv 2010; 13: 34-41 [PMID: 20879296]
34. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte- Rojo A, Wong D, Beaton M, Levstik M, Crotty P, Elkashab M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208 [PMID: 21898479 DOI: 10.1002/hep.24624]